| [1] |
Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease[J]. Ann Rheum Dis, 2020, 79(1): 77-87.
doi: 10.1136/annrheumdis-2019-216561
pmid: 31796497
|
| [2] |
Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmunedisease[J]. J Gastroenterol, 2003, 38(10): 982-984.
doi: 10.1007/s00535-003-1175-y
pmid: 14614606
|
| [3] |
Yamamoto M, Takahashi H, Ohara M, et al. A new conceptualization for Mikulicz’s disease as an IgG4-related plasmacytic disease[J]. Mod Rheumatol, 2006, 16(6): 335-340.
doi: 10.3109/s10165-006-0518-Y
|
| [4] |
Dahlgren M, Khosroshahi A, Petur Nielsen G, et al. Riedel’s thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum[J]. Arthritis Care Res (Hoboken), 2010, 62(9): 1312-1318.
doi: 10.1002/acr.20215
pmid: 20506114
|
| [5] |
Yamamoto M, Harada S, Ohara M, et al. Clinical and pathological differences between Mikulicz’s disease and Sjögren’s syndrome[J]. Rheumatology (Oxford), 2005, 44(2): 227-234.
doi: 10.1093/rheumatology/keh447
|
| [6] |
Otani Y, Shimura T, Nogaki T, et al. Differentiation between IgG4-related Mikulicz disease and Sjögren’s syndrome: A review case report and literature review[J]. Medicine (Baltimore), 2022, 101(52): e32617.
doi: 10.1097/MD.0000000000032617
|
| [7] |
Stone JH, Zen Y, Deshpande V. IgG4-related disease[J]. N Engl J Med, 2012, 366(6): 539-551.
doi: 10.1056/NEJMra1104650
|
| [8] |
Fujita A, Sakai O, Chapman MN, et al. IgG4-related disease of the head and neck: CT and MR imaging manifestations[J]. Radiographics, 2012, 32(7): 1945-1958.
doi: 10.1148/rg.327125032
pmid: 23150850
|
| [9] |
Suzuki A, Nagata N, Ohshima M, et al. Three-dimensional ultrasonographic imaging of Mikulicz’s disease[J]. Clin Rheumatol, 2022, 41(2): 583-584.
doi: 10.1007/s10067-021-05932-z
|
| [10] |
Xu J, Huang B, Chai JY, et al. The diagnostic insights of immunoglobin G4-related Mikulicz disease: A case description and literature analysis[J]. Quant Imaging Med Surg, 2023, 13(12): 8824-8831.
doi: 10.21037/qims
|
| [11] |
Xu SH, Luo J, Zhu CW, et al. Performance evaluation of multiple ultrasonographical methods for the detection of primary Sjögren’s syndrome[J]. Front Immunol, 2021, 12: 777322.
doi: 10.3389/fimmu.2021.777322
|
| [12] |
Sebastian A, Donizy P, Wiland P. IgG4-related disease and the spectrum of mimics in rheumatology[M]// Chronic Autoimmune Epithelitis - Sjogren’s Syndrome and Other Autoimmune Diseases of the Exocrine Glands. London: Intech Open, 2019
|
| [13] |
Moriyama M, Furukawa S, Kawano S, et al. The diagnostic utility of biopsies from the submandibular and labial salivary glands in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease[J]. Int J Oral Maxillofac Surg, 2014, 43(10): 1276-1281.
doi: 10.1016/j.ijom.2014.06.014
|
| [14] |
Wu Y, Xu ZR, Zhou WJ, et al. Immunoglobulin G4-related disease with features of Mikulicz’s disease and autoimmune pancreatitis which firstly presented as asymptomatic lymphadenopathy: A case report[J]. Chin Med J (Engl), 2015, 128(5): 706-707.
|
| [15] |
Takano KI, Yamamoto M, Takahashi H, et al. Clinicopathologic similarities between mikulicz disease and Küttner tumor[J]. Am J Otolaryngol, 2010, 31(6): 429-434.
doi: 10.1016/j.amjoto.2009.08.002
|
| [16] |
Shimizu M, Okamura K, Kise Y, et al. Effectiveness of imaging modalities for screening IgG4-related dacryoadenitis and sialadenitis (Mikulicz’s disease) and for differentiating it from Sjögren’s syndrome (SS), with an emphasis on sonography[J]. Arthritis Res Ther, 2015, 17(1): 223.
|
| [17] |
Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): General concept and details[J]. Mod Rheumatol, 2012, 22(1): 1-14.
doi: 10.1007/s10165-011-0508-6
pmid: 21881964
|
| [18] |
Poghosyan A, Misakyan M, Sargsyan A, et al. Chronic sclerosing sialadenitis (Küttner’s tumor) of the submandibular salivary gland: Our experience of one case report[J]. Clin Case Rep, 2019, 7(8): 1600-1604.
doi: 10.1002/ccr3.v7.8
|
| [19] |
Vu DL, Thieu-Thi TM, Pham MT, et al. A case report of mikulicz’s disease[J]. 2020, 37: 252.
|
| [20] |
Yu WK, Tsai CC, Kao SC, et al. Immunoglobulin G4-related ophthalmic disease[J]. Taiwan J Ophthalmol, 2018, 8(1): 9-14.
doi: 10.4103/tjo.tjo_12_17
|
| [21] |
Wu QJ, Chang J, Chen H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: A preliminary randomized controlled trial[J]. Int J Rheum Dis, 2017, 20(5): 639-646.
doi: 10.1111/1756-185X.13088
pmid: 28556584
|
| [22] |
Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients[J]. PLoS One, 2017, 12(9): e0183844.
doi: 10.1371/journal.pone.0183844
|
| [23] |
Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease[J]. Eur J Intern Med, 2020, 74: 92-98.
doi: S0953-6205(19)30467-4
pmid: 31901297
|
| [24] |
Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: A prospective, open-label trial[J]. Ann Rheum Dis, 2015, 74(6): 1171-1177.
doi: 10.1136/annrheumdis-2014-206605
pmid: 25667206
|
| [25] |
Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: Lessons from 10 consecutive patients[J]. Medicine (Baltimore), 2012, 91(1): 57-66.
doi: 10.1097/MD.0b013e3182431ef6
|
| [26] |
Andrew NH, Gajdatsy A, Selva D. Intraorbital corticosteroid injection for the treatment of IgG4-related ophthalmic disease[J]. Br J Ophthalmol, 2016, 100(5): 644-647.
doi: 10.1136/bjophthalmol-2015-307164
pmid: 26297732
|
| [27] |
Lang D, Zwerina J, Pieringer H. IgG4-related disease:Current challenges and future prospects[J]. Ther Clin Risk Manag, 2016, 12: 189-199.
|
), 靳书滨, 石光
苏公网安备32010602011670号
